Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

(NEW LINE)Warner-Lambert's Lopid

Executive Summary

(NEW LINE)Warner-Lambert's Lopid: FDA Endocrinologic & Metabolic Drugs Advisory Committee will review Helsinki Heart Study results in support of a claim for prevention of coronary heart disease on Oct. 17. Meeting will be held at National Institute of Health's Jack Masur Auditorium, beginning at 9:00 a.m. Company announced Sept. 19 that it has received a patent extension for Lopid (gemfibrozil) to Jan. 4, 1993 from the U.S. Patent and Trademark Office under the recently passed trade bill. The patient restoration is contingent on FDA approval of the new claim.

You may also be interested in...



Russia’s Sputnik V COVID-19 Vaccine Starts EU Rolling Review

The Russian backers of the vaccine’s development say that if it receives a marketing authorization in the EU, distribution could begin in June this year.

Exec Chat: Adaptive Biotechnologies Will Use T Cells To Spot Prior Infections, Including COVID-19

Adaptive chief medical officer Lance Baldo talked to Medtech Insight about the company's plans to detect prior infection using T-cells obtained from blood samples.

Executives On The Move: Genmab Promotes New CMO, BiondVax And Sprint Bioscience Pick Up New CEOs

Three new directors at Tenax Therapeutics, and a flurry of CMO and CFO appointments.

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel